Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Lot number and expiration date is imprinted in the unvarnished area.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e677690f-790f-4626-ad78-097cdb6ea540
Go to the left, look at package fotos, more recent lables, 9/22
With the unvarnished area, they must have a problem with varnish on these lables,
On the bottom bottle you can see the NDC, National Drug Code
64850-505-1
Google
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e677690f-790f-4626-ad78-097cdb6ea540
That number now follows Elite every where it goes.
https://fda.report/NDC/64850-505#64850-505-30
Amd of course it comes with lables
https://www.google.com/search?client=safari&sca_esv=b5f6560b0f349675&sca_upv=1&channel=ipad_bm&q=64850+505+label&tbm=isch&source=univ&fir=Oj8c4VoAR1Q6iM%252CV5WPVEunpkY0IM%252C_%253BzYtUT6ZUjemzeM%252CV5WPVEunpkY0IM%252C_%253Bt336OKhjd-aTwM%252CTsZ5aYBvgk80jM%252C_%253B_rCTeaTXSbyBoM%252CosbGmwyEsmbbvM%252C_%253ByuHd8q8uBBK9LM%252CDoH2qoHNz3e3kM%252C_%253BkoQDW85AmzfFqM%252Cdz_sly2gfejK4M%252C_%253BCSirtpGSHlIsXM%252Cazc3cK7BUEejwM%252C_%253BfHIP5vw3cW__zM%252CPr44zVVVTpUcsM%252C_%253BJRQcI3iLdVY16M%252CrBjSSccL3TBlaM%252C_%253BPKSPSjkw0SRa-M%252CvBddztKW4lLQHM%252C_&usg=AI4_-kSyXVGq4VrnWney0KM_ickgiJ4TeQ&biw=695&bih=964&dpr=2
Goat land is an abstract place.
Lol hopefully ELTP starts making little blue pills for EYEBEE and gang. Couldn’t even get it to 10 cents…what a bunch of fails. Anyone read that article on inflation hitting the goat markets? Troubled times ahead in Pakistan.
Im getting a Seafood Tower 3 feet tall !!!!!!!!!!!!!!!!!
Thanks,you do the same, Bruh !!!!!!!!!!!!!!!!!!!
IB_🤴🏻
Phonetics: Yieltipers
I thought the Gap was out of business. I guess we fell into the gap.
The GAP was hit. We go way back up.
Look like the correction is over based on Level 2 activity.
*walks past mirror....
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
__14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
I trust him with my cash
I trust him to make me rich
I trust him to make me retire in class.
The big question on everyone's mind is: DO YOU TRUST NasRat ??????????????????????
I know you refer to him as The Goat of all CEO's, but do you really trust him ??????????????????
IB_🤴🏻
I think all of us here buy around a million shares per week, that's why the share price just continually climbs !!!!!!!!!!!!!!!!
Or are we all a bunch of liars ........................
Hummmmm,
IB_🤴🏻
This is the ELTP board, not the SXOOF board !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
ELTP closes GREEN ............
SXOOF closes RED .............
IB_🤴🏻
I hope you will not be penalized.
This thing could explode any day
Look at Nasdaq2020 list of catalysts.
I'm sitting patiently as well. If the price drops around 10 or 11, I'll be making a large move. I have enough shares that I don't need to grab them 500k shares at a time any more, so I'm patient about where I enter again since my average price per share is under 5 cents.
I can only do $10-15 K a week
Not sure how many shares more I need ?
I’m ready for next Bear Raid , you ?
Yes. That’s much more likely reasoning than sellers due to disappointing Prasco sales and Nasrat sticking his foot in his mouth by over-hyping.
Nice bounce off the .123 gap close
Our little gem is all the ways back to .125 bid
Go ELTP
Are you saying your boss is short and that's why you are here? How many shares do they need to cover?
Anyone that constantly has to "wait" for funds to clear is no threat to real short players lol
Emperor and I are ready to step on if it comes to it.
Bear Raids will be addressed.
ELTP
You went out on a limb with that remark.
With volume running at yearly lows, it is easy for MMs to manipulate the price when anyone with a seven figure position who needs to sell for a variety of reasons unrelated to stock fundamentals( ie. a margin call on a marginable security), the MMs will walk down the price until a solid buyer steps in to take advantage of the sale price.
ON the otc low volume almost always translates to a price decline. The good news is that when a big buyer steps in, often on a positive news event such as an earnings report, the stock movement is often explosive to the upside. This will generate a lot of shudda coulda woudas among the faithful.
Do you think your boss who assigned you to this board has shares to cover?
Bold statement considering this thing has lost 61% of its value from Feb.
If it was shorted some one made a killing doing so.
Forgot to mention the load up all you can on the ride up again
Next stop .25 see everybody there!!
Since the last call? How bout last 10 years
I don’t believe shorting is the issue, but the price has been amputated since the last call that cannot he argued.
No guarantees in penny stocks...none
Especially this thing that is intertwined with a private company, and a completely conflicted
CEO.
Red again today, i guarantee it.
These impotent shorts can’t do anything they say they can do. What a disappointment.
You mean you aren’t always sitting flush with cash in your brokerage account like eatman “is” ? How unfortunate that you aren’t extravagantly wealthy enough to troll a penny stock message board daily for over a decade…
lol lol
Up
Every day we have more chance for pr.
Lower Lows & Lower Highs !!!!!!!!!!!!!!!!!!!!!!!!!!!
If you want a lower share price, NasRat's dilution is your friend,
IB_🤴🏻
Correct, but no one knows when!!
Picked up a little over 20,000 shares this morning at .124. All I had to spend today got much more coming next week.
Quote: "Stfu and drop it 2.5 more ELTP Emperor" !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_🤴🏻
I'll take 3% every day
Good volume, a little green, let's see how the day ends
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite Dexcel |
Adderall XR | 1.56 B | On Market | 10 | Elite Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 47 M | On Market | 5 | Elite |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 477 M | Approved in Launch Queue | 12 | ---------- |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | 4 | ---------- |
Vyvanse | 4.70 B | Filed with FDA - 21 Dec 2023 | 11 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,063 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | ||||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |